Table 3 Demographic characteristic and biochemical analysis in MS and control sub-groups
From: Reduction in circulating vitamin D binding protein in patients with multiple sclerosis
Demographic characteristic | MS (N = 77) | Control (N = 67) | p-value |
|---|---|---|---|
Age (years)†| 33.68 ± 8.16 | 34.71 ± 6.45 | 0.89 |
Sex (Women)‡ | 76.9% (60) | 76.6% (52) | 0.94 |
BMI (kg/m2)†| 24.66 ± 4.47 | 24.19 ± 3.81 | 0.49 |
Clinical outcomes | |||
 MS Duration (month)††| 4.02 (8) | – |  |
 MS diagnosis age (years)†| 33.60 ± 7.81 | – |  |
 Smoking‡ | 10.0% (7) | 6.0% (4) | 0.52 |
 Vitamin D levels†| 33.60 ± 14.91 | 21.55 ± 12.49 | 0.0001 |
 Ln. VDBP levels (μgr/ml) †| 3.64 ± 0.91 | 5.31 ± 0.77 | 0.0001 |
Albumin (g/dl)†| 4.07 ± 0.81 | 4.10 ± 0.85 | 0.89 |
Taking vitamin D supplement ‡ | |||
 Regular | 54.5% (42) | 18.0% (12) | 0.0001 |
 Irregular | 17.0% (13) | 35.8%(24) | |
 Never | 28.5% (22) | 46.2% (31) | |
Taking drug at the sampling time‡ | |||
No treatment | 32.5% (25) | – |  |
Rituximab | 11.7% (9) | – |  |
Natalizumab | 2.6%(2) | – |  |
 Interferon B1a | 26.0% (20) | – |  |
 Glatiramer acetate | 9.1% (7) | – |  |
 Dimethyl fumarate | 2.6% (2) | – |  |
 4 Aminopyridin | 1.3% (1) | – |  |
 Fingolimod | 13.0% (10) | – |  |
 Teriflunomide | 1.3% (1) | – |  |
 Corticosteroids | – | – |  |